Avoid unnecessary biopsies. Get a clear picture of your prostate cancer risk – with a simple blood test.
Exceptional Accuracy – Significantly more accurate than a standard PSA test, reducing the risk of overdiagnosis and unnecessary treatments.
A Revolutionary Test That Prevents Biopsies – Enables approximately 40% of patients to avoid an invasive, painful, and unnecessary biopsy.
Personalized Risk Score – Clear and understandable result in percentage form, supporting informed and shared decision-making between doctor and patient.
Included in Expert Guidelines – Recommended by international guidelines such as NCCN and EAU as a complementary test before biopsy.
Wide Insurance Coverage – Reimbursement available through Clalit, Meuhedet, and Leumit health funds depending on insurance plan.
The 4Kscore Test is an advanced blood test based on the measurement of four blood biomarkers (Total PSA, Free PSA, Intact PSA, and hK2) and a statistical algorithm. Together, they provide an accurate estimate of the risk of having prostate cancer with a Gleason score of 7 or higher. The test result is presented as a percentage reflecting the likelihood of finding aggressive cancer if a biopsy were to be performed.
A standard blood sample is collected at a certified service point.
Quantification of kallikrein proteins and assessment of clinical parameters.
An algorithm generates a risk score predicting the presence of aggressive prostate cancer.
A full clinical report is delivered to the referring physician within several business days.
Men with elevated or rising PSA values, before undergoing a first biopsy.
Men who had a negative biopsy but clinical suspicion of prostate cancer remains.
